Bridging the Racial Disparity Gap in Lipid‐Lowering Therapy

Kalra, Dinesh K.

doi:10.1161/jaha.120.019533

Cited by 18 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,3 However, little is known about how population trends in lipid concentrations-another major risk factor for cardiovascular disease-changed from 2007 through 2018. [4][5][6] Although older and/or smaller-scale studies suggest variation in cholesterol concentrations across racial and ethnic groups, [7][8][9][10] nationally representative estimates of lipid trends in the US population, as well as control rates, have not been recently examined by race and ethnicity. 6,7,[11][12][13] In addition, to our knowledge, surveillance data for Asian and Mexican American adults have either not been reported or limited by small sample size; therefore, patterns in these subgroups have not been well characterized on a national scale.…”

mentioning

confidence: 99%

Trends in Lipid Concentrations and Lipid Control Among US Adults, 2007-2018

Aggarwal

Bhatt

Rodríguez

et al. 2022

JAMA

View full text Add to dashboard Cite

Key PointsQuestionDid lipid concentrations in the US population change from 2007-2008 to 2017-2018, and how did these patterns differ across subgroups?FindingsIn this serial cross-sectional study of 33 040 adults, mean age-adjusted total cholesterol concentrations significantly declined in the US population from 197 mg/dL in 2007-2008 to 189 mg/dL in 2017-2018. This pattern was consistent across all racial and ethnic subgroups, with the exception of non-Hispanic Asian adults.MeaningMean cholesterol concentrations improved among US adults from 2007 to 2018, although there was variation in these trends by race and ethnicity.

show abstract

mentioning

confidence: 99%

Trends in Lipid Concentrations and Lipid Control Among US Adults, 2007-2018

Aggarwal

Bhatt

Rodríguez

et al. 2022

JAMA

View full text Add to dashboard Cite

show abstract

“…Opportunities exist to reduce barriers to post-diagnosis care for children with FH through increasing training in primary providers and providing additional resources for families after diagnosis. Future studies are needed to identify other key barriers and resources for providers as well as parents who are caring for children with FH, especially when disparities in treatment have been shown to exist among pediatric and adult patients with FH (Amrock SM et al 2017;de Ferranti SD et al 2021;Kalra DK 2021;Langslet G et al 2021).…”

Section: Family History Is a Facilitator For Pediatric Fh Diagnosismentioning

confidence: 99%

“I don’t think people should die young”: Perspectives of parents with children diagnosed with familial hypercholesterolemia

Tsai,

Young,

Cherny

et al. 2024

Preprint

View full text Add to dashboard Cite

Familial Hypercholesterolemia (FH) is an inherited disorder that significantly increases an individual’s risk of developing premature cardiovascular disease (CVD). Early intervention involving lifestyle modification and medication is crucial in preventing CVD. Prior studies have shown that lipid-lowering therapy in children is safe and effective. Despite FH being a treatable and manageable condition, the condition is still underdiagnosed and undertreated. Universal lipid screening (ULS) in children has been recommended by some medical experts in the United States as a strategy to identify cases of FH and maximize the benefits of early invention. However, lipid screening is not routinely offered in pediatric clinics. This study aimed to explore parental experience with FH diagnosis in their children, identify key facilitators and barriers in children’s diagnosis and care, and examine parental perspectives on ULS in children in the United States. A total of fourteen semi-structured interviews were conducted with participants recruited through the Family Heart Foundation. Thematic analysis identified three key themes: role of family history in facilitating child’s FH diagnosis, barriers and challenges in post-diagnosis care, and attitudes towards ULS in children. All participants supported ULS in children and emphasized the value of early diagnosis and treatment for FH. However, a lack of guidance or referral after the child's diagnosis was a concern raised by many participants. This underscores the need for accessible and comprehensive care amid ongoing efforts to increase pediatric diagnosis of FH.

show abstract

Section: Facets Of Statin Therapy In Nhopimentioning

confidence: 99%

“…Discerning effects of several lipid-lowering drugs can be seen in different ethnic groups because of variations in genetic background, sex, drug metabolism, and environmental factors, such as diet, stress levels, alcohol consumption, and medication adherence ( 7 ). Differences in statin blood levels, pharmacokinetics, and their efficacy and adverse effects are known to be caused by genetic variations among populations ( 7 , 38 ). Potential genetic variations have been linked to differential response to statin and statin-related side effects, explaining ethnicity as a source of response variability observed between Asians and Americans.…”

Section: Facets Of Statin Therapy In Nhopimentioning

confidence: 99%

“…Nevertheless, significant side effects, such as muscle disorders, have been associated with statin use ( 6 ). The occurrence of statin side effects varies among different ethnic groups and is associated with individual intrinsic factors or external aspects ( 7 ). Therefore, identifying the most impactful determinants that can be modified to prevent or reduce statin side effects in the NHOPI population is essential to developing interventions that best meet the needs of this population ( 7 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Challenging Aspects to Precise Health Strategies in Native Hawaiian and Other Pacific Islanders Using Statins

Watanabe

Seale

2022

Front. Public Health

View full text Add to dashboard Cite

Cardiometabolic disorders (CD), including cardiovascular disease (CVD), diabetes, and obesity, are the leading cause of health concern in the United States (U.S.), disproportionately affecting indigenous populations such a Native Hawaiian and Other Pacific Islanders (NHOPI). Dyslipidemia, a prevalent risk factor for the development and progression of CVD, is more prone to occur in NHOPI than other populations in the U.S. High-intensity statin therapy to reduce low-density lipoprotein cholesterol is associated with the prevention of CVD events. However, significant side-effects, such as muscle disorders, have been associated with its use. Different ethnic groups could experience variation in the prevalence of statin side effects due to sociodemographic, behavioral, and/or biological factors. Therefore, identifying the most impactful determinants that can be modified to prevent or reduce statin side effects for individuals from high-risk ethnic minority groups, such as NHOPI, can lead to more effective strategies to reduce health disparities. Thus, our Mini-Review explores the challenging aspects of public health precise strategies in NHOPI taking statins, including a culturally informed additional therapy that could positively impact the NHOPI population.

show abstract

Bridging the Racial Disparity Gap in Lipid‐Lowering Therapy

Cited by 18 publications

References 17 publications

Trends in Lipid Concentrations and Lipid Control Among US Adults, 2007-2018

Trends in Lipid Concentrations and Lipid Control Among US Adults, 2007-2018

“I don’t think people should die young”: Perspectives of parents with children diagnosed with familial hypercholesterolemia

Challenging Aspects to Precise Health Strategies in Native Hawaiian and Other Pacific Islanders Using Statins

Contact Info

Product

Resources

About